Regenxbio

RGNX NASDAQ
35.07
-1.73
-4.70%
After Hours: 35.07 0 0.00% 16:36 08/22 EDT
Open
36.77
Prev Close
36.80
High
36.77
Low
35.00
Volume
471.44K
Avg Vol (3M)
580.32K
52 Week High
83.45
52 Week Low
35.00
% Turnover
1.20%
Market Cap
1.29B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Regenxbio RGNX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.
MORE >

Recently

Name
Price
%Change